- Home
- CINT vs PVLA Comparison
CINT vs PVLA Comparison
Compare CINT & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CINT
- PVLA
- Stock Information
- Founded
- CINT 1995
- PVLA 2015
- Country
- CINT Brazil
- PVLA United States
- Employees
- CINT N/A
- PVLA N/A
- Industry
- CINT EDP Services
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- CINT Technology
- PVLA Health Care
- Exchange
- CINT Nasdaq
- PVLA Nasdaq
- Market Cap
- CINT 670.2M
- PVLA 604.2M
- IPO Year
- CINT 2021
- PVLA N/A
- Fundamental
- Price
- CINT $5.08
- PVLA $73.85
- Analyst Decision
- CINT Strong Buy
- PVLA Strong Buy
- Analyst Count
- CINT 5
- PVLA 12
- Target Price
- CINT $7.36
- PVLA $68.67
- AVG Volume (30 Days)
- CINT 285.5K
- PVLA 199.5K
- Earning Date
- CINT 11-13-2025
- PVLA 11-15-2025
- Dividend Yield
- CINT N/A
- PVLA N/A
- EPS Growth
- CINT 34.66
- PVLA N/A
- EPS
- CINT 0.25
- PVLA N/A
- Revenue
- CINT $452,826,000.00
- PVLA N/A
- Revenue This Year
- CINT $12.57
- PVLA N/A
- Revenue Next Year
- CINT $12.91
- PVLA N/A
- P/E Ratio
- CINT $20.22
- PVLA N/A
- Revenue Growth
- CINT 1.02
- PVLA N/A
- 52 Week Low
- CINT $3.98
- PVLA $11.17
- 52 Week High
- CINT $8.00
- PVLA $77.77
- Technical
- Relative Strength Index (RSI)
- CINT 59.24
- PVLA 59.32
- Support Level
- CINT $4.13
- PVLA $70.55
- Resistance Level
- CINT $5.17
- PVLA $77.77
- Average True Range (ATR)
- CINT 0.23
- PVLA 4.49
- MACD
- CINT 0.11
- PVLA -0.67
- Stochastic Oscillator
- CINT 92.56
- PVLA 66.89
About CINT CI&T Inc
CI&T Inc is engaged in providing plans, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.